Individuals with benign tumor or early stage of OSCC had lower levels of plasma natural anti-HER2 antibodies than controls subjects, suggesting that natural anti-HER2 antibodies play a crucial role in preventing tumorigenesis by inhibiting the growth of both OSCC and benign tumors. Here, ERBB2 is linked to benign neoplasm.